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2Abstract:
De novo designed peptide based super secondary structures are expected to provide 
scaffolds for the incorporation of functional sites as in proteins. Self-association of 
peptide helices of similar screw sense, mediated by weak interactions has been probed 
by the crystal structure determination of two closely related peptides:
Ac-Gly1-Ala2-∆Phe3-Leu4-Val5-∆Phe6-Leu7-Val8-∆Phe9-Ala10-Gly11-NH2, I and Ac-
Gly1-Ala2-∆Phe3-Leu4-Ala5-∆Phe6-Leu7-Ala8-∆Phe9-Ala10-Gly11-NH2, II. The crystal 
structures determined to atomic resolution and refined to R-factors 8.12% and 4.01% 
respectively reveal right-handed 310-helical conformations for both the peptides. 
Circular dichroism has also revealed the preferential formation of right-handed 310-
helical conformations for both the molecules. Our aim was to critically analyze the 
packing of the helices in the solid state with a view to elicit clues for the design of 
super secondary structural motifs such as two, three and four helical bundles based on 
helix-helix interactions. An important finding is that a packing motif could be 
identified common to both the structures, in which a given peptide helix is surrounded 
by six other helices reminiscent of transmembrane seven helical bundles. The outer 
helices are oriented either parallel or antiparallel to the central helix. The helices 
interact laterally through a combination of N-HLO, C-HLO and C-HLπ hydrogen 
bonds. Layers of interacting Leucine residues are seen in both the peptide crystal 
structures. The packing of the peptide helices in the solid state appears to provide 
valuable leads for the design of super secondary structural modules such as two, three 
or four helix bundles by connecting adjacent antiparallel helices through suitable 
linkers such as tetraglycine segments.
3Introduction:
De novo protein design endeavors to understand the daunting complexity of protein 
architecture and has the ambitious goal of constructing novel molecules with 
predetermined structures and functions.1-4 The success in the de novo synthesis of 
protein mimics, 5-12 relies heavily on the ability to design relatively short peptides that 
can adopt stable secondary structures, such as a helix. In this connection, non-protein 
amino acids such as α,β-dehydrophenylalanine (∆Phe) have been used as 
conformation-determining residues.13-21 A recent example from our laboratory 
includes, a ∆Phe containing decapeptide, showing self-association of opposite-
handedness helices.22 This self-association concept was successfully exploited by us 
in the design of super secondary structure helix-turn-helix, where the adjacent helices 
that docked to each other are of opposite screw sense.23 However, a strategy has to be 
evolved for the development of discrete folded super secondary structural motif in 
which the interacting helices are right-handed, for which there has been till date no 
crystal structure containing ∆Phe residue as a model for pairing and interaction. Here, 
we report the synthesis and characterization of two closely related undecapeptides 
namely: Ac-Gly1-Ala2-∆Phe3-Leu4-Val5-∆Phe6-Leu7-Val8-∆Phe9-Ala10-Gly11-NH2, I; 
and Ac-Gly1-Ala2-∆Phe3-Leu4-Ala5-∆Phe6-Leu7-Ala8-∆Phe9-Ala10-Gly11-NH2, II; that 
have been envisioned to fold as right-handed 310-helices. Val residues at positions 5 
and 8 in peptide I have been replaced by less bulky Ala residues in peptide II, except 
for which the two sequences are similar. Crystal structure and CD studies have both 
confirmed the preferential folding of the designed peptides into right-handed 310-
helices. Interestingly in both the crystal structures, a given helix is surrounded by six 
other helices reminiscent of transmembrane seven helical-bundles. The outer helices 
4have either parallel or antiparallel orientation relative to the central helix. Apart form 
other interactions the parallel helices interact through C-H…O24 and C-H…π25 
hydrogen bonds while the antiparallel helices interact through N-H…O and C-H…π
hydrogen bonds. Leucine residues occurring in layers is a feature common to both the 
structures.  Here we discuss the molecular and crystal structures of the peptides I and 
II and the clues that have emerged to realize the successful design of higher order 
super secondary structural elements such as helical bundles.
Experimental procedures
Synthesis and characterization of peptides
Fmoc-protected amino acids for solid-phase peptide synthesis were obtained from 
Novabiochem or Bachem. The two undecapeptides (I and II) were synthesized 
manually at a 0.5 mmol scale. Fmoc-Rinkamide MBHA (Novabiochem) resin 
(0.5mmol/g) was used to afford carboxyl-terminal primary amides. Couplings were 
performed by using carbodiimide. Solution phase methodology was used to 
introduce the ∆Phe residue in the undecapeptides as a dipeptide block by 
dehydration of Fmoc-Aa-DL-threo-β-Phenyl Serine (Aa=Valine or Alanine in 
case of (I) and aa=Alanine in case of (II)) using fused sodium acetate and freshly 
distilled acetic anhydride as reported earlier.26 All reactions were monitored by 
TLC on precoated silica plates in at least two different solvent systems.26 All the 
couplings were followed by a 5 minute reaction with acetic anhydride and HOBT in 
DMF/DCM to cap any unreacted amines. Fmoc deprotection was performed with 
piperidine (20% in DMF). After addition of the final residue, the amino terminus was 
acetyl-capped and the resin was rinsed with DMF/DCM/MeOH then dried. The final 
peptide deprotection and cleavage from the resin was achieved with 10 ml of 
595:2.5:2.5 TFA: H2O: triisopropylsilane for 2 hours. The resin was filtered and the 
filtrate concentrated to ca. 1 ml volume after which the crude peptides were 
precipitated with cold ether. The supernatant was decanted and crude peptides were 
suspended in water with a minimal amount of acetonitrile then frozen and lyophilized 
to dryness. The lyophilized crude peptides were dissolved in DMSO and purified by 
preparative reverse phase HPLC (RP-HPLC) (C5 SUPELCO PREP 
Column/Shimadzu HPLC/linear gradient 40-60% acetonitrile (0.1%TFA)/H2O 
(0.1%TFA) over 50 min). Peptide identities were confirmed on a mass spectrometer. 
(I) (C61H82N12O12) calculated 1174 Daltons, observed 1197 Daltons (sodium salt); 
(II) (C57H74N12O12) calculated 1118 Daltons, observed 1141 Daltons (sodium salt). 
The α,β-dehydrophenylalanine residues in both the peptides correspond to the 
Z-isomer27 (∆Z Phe) and the symbol ∆Phe is used here to represent ∆Z Phe.
X-ray Crystallography:
The peptide, I; (C61H82N12O12, MW = 1197) was crystallized by controlled slow 
evaporation of the peptide solution in a (1:1 v/v) mixture of acetone-ethanol. Platy 
crystals were obtained over a period of 15 days. For the suitable crystal, X-ray 
diffraction data was collected on a Bruker AXS SMART APEX CCD diffractometer 
equipped with MoKα radiation (λ=0.71073 Å). The structure solution was obtained 
by using direct methods as employed in Shake and Bake28 (SnB). The structure was 
refined to an R-factor of 8.12%. No solvent molecules could be located in the electron 
density map. The crystallographic details of this peptide are summarized in Table 1. 
The peptide, II; (C57H74N12O12, MW = 1141) was crystallized by controlled slow 
evaporation of the peptide solution in a methanol-water mixture. Good platy crystals 
were obtained over a period of 7 days. X-ray diffraction data was collected on a 
6Bruker AXS SMART APEX CCD diffractometer equipped with Mo Kα radiation 
(λ=0.71073Å). The structure solution was obtained by using direct methods employed 
in SHELXS29.  The structure was refined to an R-factor of 4.01%. No solvent 
molecules could be located in the electron density map. The crystallographic details 
of this peptide are summarized in Table 1.
Circular Dichroism spectroscopy:
Circular dichroism (CD) measurements were carried out on a JASCO J720 
spectropolarimeter with a data processor attached. A 1mm pathlength was used. The 
spectrum was recorded in various solvents such as acetonitrile (ACN), 
dichloromethane (DCM), chloroform (CHCl3), methanol (MeOH), trifluoroethanol 
(TFE) and dimethylsulfoxide (DMSO).
Results and Discussions:
Molecular and Crystal structures of Peptide I and Peptide II:
Molecular conformations:
Atomic resolution structures of peptides I and II are depicted in the Figure 1. As 
designed, both peptides folded into right-handed 310-helices. In both of these peptide 
molecules, the segments 2-9 are in 310-helical conformations (Table 2), stabilized by 
4→1 hydrogen bonds as shown in Table 3.  The average (φ, ψ) values for helical 
stretch in Peptide I and II are (-56°, -20°) and (-57°, -21°) respectively. 
In 310-helices, every third residue lies on the same face of the helix. Accordingly in 
both structures, peptide I and II, three ∆Phe residues (∆Phe3, ∆Phe6, ∆Phe9), which 
are placed at two-residue spacer in sequence during design, lie on the same face of 
7helix, similarly Leu4, Leu7, and Ala10 lie on the same face of helix.  The rest Ala2, 
Val5, Val8 residues are on the same face of helix in peptide I and Ala2, Ala5, Ala8 
residues on the same side of helix in peptide II as is clearly seen in Figure 1. Figure 
(1b, 1d) also depicts the occurrence of wedges and grooves defined by the main chain 
and protruding side chain atoms, a characteristic feature of 310-helices.  The least 
square superposition30 of the corresponding main chain atoms of peptides I and II 
results in an R.M.S.D of 0.36Å indicating that both the peptides have very nearly the 
same backbone conformation.
CD studies
CD spectroscopy can be a very useful tool to establish the screw sense of 
dehydrophenylalanine containing peptides.31 The CD spectra displays a couplet of 
bands that appear as a typical exciton splitting of the dehydrophenylalanine 
chromophore at 280 nm. This splitting pattern is an indication of two or more ∆Phe 
residues, generally involved in a system of consecutive beta-turns, i.e. 310-helix,
 32,33
the sign of the couplet dictating the handedness of the helices. For the present 
undecapeptides, CD studies were carried out in various solvents at room temperature. 
The spectra display couplet of bands, the most striking feature being the sign of the 
couplet. A negative CD couplet (- +), characteristic of a right-handed 310-helix with 
negative band at 299 nm, a positive band at 268 nm and a crossover point at λ=287 
nm is observed for the undecapeptides in various solvents tried. Thus the 
undecapeptides preferentially form a right-handed 310-helical conformation. The sign 
of the couplet does not change with the solvent. Only a variation in the intensity of the 
couplet is observed which reflects the instability of the peptide conformation in 
different solvents. Both the peptides, however, show small featureless CD spectra in 
DMSO, suggesting loss of structure in this chaotropic solvent (CD data not shown).  
8Crystal packing: 
Arrangement of helices: 
It is very interesting to note that, despite differences between their sequences, both 
these peptides have crystallized in same space group P21 21 21 and with quite similar 
cell parameters (Table 1). In the crystal packing of both molecules, peptide I and II, 
the helices are arranged in both antiparallel and parallel orientations. Figure (2a - d) 
shows view down the helical axis for the helical arrangement in crystal lattice of 
Peptide I and II, when they are in antiparallel and parallel orientations. 
Further, the helices are arranged laterally in such a way that they are in level with 
each other and a given helix is surrounded by six other helices, two helices being 
parallel and four helices being antiparallel to it. Figure (3a - d) shows such packing of 
helices in a layer.  This arrangement has resulted in two kinds of helix interfaces, Leu 
– Leu and Val – Val in case of Peptide I and Leu – Leu and Ala – Ala in case of 
peptide II. In (Figure 4a, c) it is clearly seen that helices in central row are having 
Leucine – Leucine interface with those in upper row in both crystal structures. While 
helices in central row are having Valine – Valine or Alaine – Alaine interface with 
those in lower row in peptide I and II respectively. Figure 5e depicts the schematic 
representation of packing of helices and the naming of peptide chains in both peptides 
I and II.
Association of Helices:
In both the cases of helical arrangements, the parallel and antiparallel, the helices are 
associated through wedges into grooves (Figure 2, 3a, c) as opposed to knobs into 
holes in α-helices in proteins34. In Leu – Leu interfaces of both peptides, and Ala –
Ala interface in Peptide II, there were no close approaches of methyl moieties. Their 
9C…C distance were > 4.0 Å except in the case of Cγ1(Val8)…Cγ2(Val5) = 3.4 Å, in 
Peptide I at the Val – Val interface.
Hydrogen Bonding Network:
In crystal packing of both the peptides, helices are found to have head-to-tail kind of 
hydrogen bonds N2LO9’, N3LO11’ and N12LO1 (Table 3) in a direction parallel 
to the helical axis.  In addition to other non-bonding interactions (wedges into 
grooves, helix dipole – dipole interactions), packing of helices along lateral direction 
are further stabilized by network of classical N-HLO hydrogen bonds N1LO10’ 
(Table 3) and non-classical C-HLO and C-HLπ weak hydrogen bonds (Table 4). 
Figure 4 explicitly shows the occurrence of the intermolecular hydrogen bonds. There 
is a distribution of type and concentration of hydrogen bonds in the packing of the 
helices.  In the crystal structures of both the peptides, parallel helices interact through 
aromatic side-chain of ∆Phe to main chain C-H…O hydrogen bonds (Figure 4a,b and 
Table 4), three C-H…O bonds between parallel helices in the case of peptide I and 
two in the case of Peptide II.  In addition to the three C-H…O bonds, parallel helices 
are having a C-H…π bond at termini in case of peptide I. At Leu – Leu interface, 
common to both crystal packing the antiparallel helices are engaged in a N-H…O 
hydrogen bond at termini. In addition, in case of Peptide II a C-H…π bond is found 
between antiparallel helices (Figure 4b, d, f and Table 4).  At Val-Val interface in 
Peptide I, antiparallel helices are interacting through two C-H…π bonds (Figure 4e 
and Table 4). While at Ala – Ala interface, in Peptide II, a C-H…π bond is observed 
between antiparallel helices (Figure 4f and Table 4). 
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This network of hydrogen bonds in a direction lateral to the helices can be represented 
schematically as shown in Figure 5. In case of Peptide I each helix is involved in a 
total of two N-H…O hydrogen bonds, six C-H…O and six C-H…π intermolecular 
hydrogen bonds. In case of Peptide II each helix is involved in a total of two N-H…O 
hydrogen bonds, four C-H…O and four C-H…π intermolecular hydrogen bonds. 
Thus in the crystal structure of these peptides, each helix is acting as donor and 
acceptor of intermolecular hydrogen bonds.
Presumably, the presence of well defined wedges and grooves in 310-helices 
encourage the bringing together of adjacent helices facilitated by wedge into groove 
association resulting in the occurrence of a multitude of classical as well as non-
classical interactions at the helix interfaces. The overall arrangement of helices in the 
crystal structure of these two peptides may be best described as a hexagonal close 
packing of regular cylinders where the cylinders are in flush with each other.
A careful study and a proper understanding of interactions between helices and the 
pattern of their association is important, since it has been reported recently that both 
metal binding and catalytic activity could be successfully incorporated into a hetero 
oligomeric association of de novo designed peptide helices as tetramers35.
Discussions:
In the crystal structures of both molecules Peptide I and II, identical helical 
arrangements are observed. A given helix is surrounded by two parallel and four 
antiparallel helices. This mode of aggregation of helices via the parallel and 
antiparallel orientations is similar to that observed in membrane proteins36 and water-
soluble proteins including helical bundles.  Parallel and antiparallel and only parallel 
arrangements of α-helices in crystal polymorphism were observed for Aib containing 
decapeptides 37,38, where the packing of helices was reportedly dominated by the close 
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approach of methyl moieties (3.4 – 4.1 Å). But in the present peptide molecules, 
helical packing seems to be stabilized by concerted action of weak C-H...O, C-H...π
and classical N-H...O hydrogen bonds along with other non-bonding interactions and 
close approach of methyl moieties does not seem to be dominating the helical 
packing. A comparison of calculated crystal densities (Table 1) of the Peptide I and II 
(1.22 g/cm3 each) with those of Aib containing decapeptides37, 38 (1.161, 1.117, 1.120, 
1.126 and 1.143 g/cm3) suggests that packing of helices in crystal structures of 
Peptide I and II is more compact. This can presumably be attributed to the presence of 
hydrogen bond networks, other reason being smaller radius of 310-helices compared to 
that of α helices39 and wedges into groves association of 310-helices that brings them 
together. In the recently reported helix-turn-helix structure from our laboratory a 
tetraglycine segment links adjacent antiparallel helices.21 The folding of the peptide 
was realized through a concerted action of C-H…O and N-H…O hydrogen bonds 
between helices. The self association of helices in the crystal structures of peptides I 
and II reported here, the occurrence of a common helix packing motif in the two 
crystal structures and the presence of C-H…O, C-H…π and N-H…O hydrogen bonds 
between the helices in the lateral direction, points to the possibility of controlled 
design of covalently linked helical aggregates and the construction of real helical 
bundles.40
Conclusions:
As designed, peptides I and II have folded into right-handed 310-helical conformation.
Despite the differences between their sequences, both peptide molecules have 
identical helical arrangements in the crystal packing; a given helix is surrounded by 
six other helices, two helices being parallel and four being antiparallel to the central 
helix. The packing of helices is characterized by a network of hydrogen bonds along 
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with other non-bonded interactions.  These hydrogen bonds include conventional N-
H…O and a multitude of weak C-H…O and C-H…π weak hydrogen bonds. 
Weak interactions along with other non-bonded interactions that determine the 
stability of the supramolecular system and play an important role in their folding.41, 
42,43 appear to dictate the packing of helices in both the crystal structures. The 
occurrence of conventional N-H…O hydrogen bond between adjacent antiparallel 
helices appears to further stabilize the helix association.  
The lateral association of right-handed helices observed in the crystal structures of 
peptides I and II can be exploited for the construction of super secondary structures 
like helical-hairpin, triple and four-helix bundles. This could be achieved by the 
covalent insertion of flexible residues (tetraglycine linker segment) between the 
adjacent helices. For example, the adjacent antiparallel helices A and G (Figures 2, 3) 
may be connected to form a helical hairpin and the helices A, G and C may be 
connected sequentially to form a three-helix bundle. There are many examples where 
the self-association of molecules has led to the design of super secondary structural 
elements21, 23, 44. In these molecules, tetraglycine linker has been used as a connecting 
segment between adjacent helices resulting in the successful design of peptide based 
super secondary structural modules.
The crux of our design strategy involves the use of conformation-constraining amino 
acid residue ∆Phe to induce long- range interactions. As may be seen, the aromatic 
ring in the ∆Phe residue acts as a donor in C-H…O interactions and as an acceptor in 
C-H...π interactions in both the crystal structures. Also, the careful positioning of 
other protein-coded hydrophobic amino acid residues has helped us realize both 
parallel and antiparallel orientation of the right-handed helices. The association of the 
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right-handed 310-helices through the concerted action of N-H...O, C-H...O and C-H...π
interactions has provided possible clues for the construction of helical bundles. There 
is an advantage in including the ∆Phe residue in the design of super secondary 
structural elements as it exhibits preferential secondary structural features, i.e., helix 
inducer, both in solid state and in solution and provides greater stability to the 
scaffold. The design of higher order super secondary structural elements using ∆Phe 
is likely to be helpful in realizing stable molecular frameworks for incorporating 
activity.
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Table 1.  Data collection and Refinement parameters for Ac-Gly-Ala-∆Phe-Leu-
Xxx--∆Phe-Leu-Xxx--∆Phe-Ala-Gly-NH2. (Xxx=Val  I, Xxx=Ala II) 
Peptide I Peptide II
Empirical Formula C61 H82 N12 O12 C57 H74 N12 O12
Molecular weight 1174 1118 
Crystal System Orthorhombic Orthorhombic
Space Group P212121 P212121
Cell Parameter a=10.69Å, b=15.37 Å, 
c=38.95 Å
a=10.73 Å, b=14.56 Å, 
c=39.08 Å
Cell Volume V=6400 Å3 V=6105 Å3
     Z 4  4
Molecules/asymmetric 
Unit
1  1
Density Calculated 1.22 g cm-3 1.22 g cm-3 
µ 9.0 cm-1 9.0 cm-1 
Radiation used Mo (λ=0.71073 Å) Mo (λ=0.71073 Å)
Resolution 1.00 Å 0.9 Å
Unique reflections 6711 8755
Observed reflections 5383 (|Fo| > 4σ(|Fo|) 7331 (|Fo| > 4σ(|Fo|)
Structure Solution SnB V2.1 Shelxs
Refinement Procedure Full-matrix least-squares 
refinement on Fo2 using 
Shelxl (97-2)
Full-matrix least-squares 
refinement on Fo2 using 
Shelxl (97-2)
Number of parameter 
refined
767 737
Data/Parameter 7.0 9.95
R-factor 8.12% 4.01%
wR2 17.43% 8.73%
GooF (s)
Residual electron density
1.119
Max. =0.39e/Å3
Min= -0.24e/Å3
1.047  
Max. =0.13e/Å3
Min. =-0.12e/Å3
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Table 2.  Torsion angles (deg) in the peptides, Ac-Gly-Ala-∆Phe-Leu-Xxx--∆Phe-
Leu-Xxx--∆Phe-Ala-Gly-NH2. (Xxx=Val  I, Xxx=Ala II) 
Peptide I
    Residue Phi Psi Omega Chi1 Chi2
1 GLY -71 168 -179
2 ALA -50 -34  179
3 ∆PHE -53 -22  176 -3 -17
4 LEU -59 -16  174 -114 -178
5 VAL -61 -16  170 -55
6 ∆PHE -52 -21 -177  0 -21
7 LEU -66 -2  162 -66 179
8 VAL -54 -26  170 -69
9 ∆PHE -53 -20  178 -4 -40
10 ALA -93  3 -178
11 GLY -108 -177
Peptide II.
    Residue Phi Psi Omega Chi1 Chi2
1 GLY -77  169 -179
2 ALA -50 -33  179
3 ∆PHE -59 -17  173 -4 -16
4 LEU -61 -14  171 -69  177
5 ALA -49 -32  179
6 ∆PHE -55 -23 -180  3 -6 
7 LEU -71 -3  162 -61  177
8 ALA -53 -27  172
9 ∆PHE -55 -17  177 -3 -30
10 ALA -86   0 -180
11 GLY -96  178
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Table 3.  Hydrogen bonds in the structures of peptides, Ac-Gly-Ala-∆Phe-Leu-
Xxx--∆Phe-Leu-Xxx--∆Phe-Ala-Gly-NH2. (Xxx=Val  I, Xxx=Ala II) 
Peptide I
Peptide II
• 0)  x, y, z 
1) ½+x, -y+½, -z             2) -x+½+1, -y, z-½             3) –x+½, -y, z+½
Type D (Donor) A (Acceptor) DLA (Å) HLA (Å) D-HLA 
(°)
Symmetry
code*
   Lateral N1 O10’ 2.950 2.09   174         1
   Head-to-
   Tail
 N2
 N3
 O9’
O11’
2.771
3.116
1.97
2.19
155
171
2
2
  310-helix  N4  O1’ 2.966 2.11 171 0
    (4→1)  N5  O2’ 3.063 2.20 178 0
 N6  O3’ 3.033 2.18 169 0
 N7  O4’ 2.980 2.13 172 0
 N8  O5’ 3.024 2.17 176 0
 N9  O6’ 2.904 2.06 167 0
 N10  O7’ 2.881 2.06 161 0
 N11 O8’ 3.003 2.17 163 0
Head-to-Tail N12 O1’ 2.774 1.92 171 3
Type D (Donor) A (Acceptor) DLA (Å) HLA (Å) D-HLA (°) Symmetry 
code*
Lateral  N1 O10’ 2.879 2.03 169 1
Head-to-Tail  N2 O9’ 2.810 1.99 159 2
 N3  O11’ 2.947 2.10 170 2
310-helix  N4  O1’ 2.958 2.11 169 0
(4→1)  N5  O2’ 2.935 2.09 169 0
 N6  O3’ 3.056 2.21 168 0
 N7  O4’ 2.917 2.08 165 0
 N8  O5’ 2.991 2.14 171 0
 N9  O6’ 2.902 2.08 161 0
 N10  O7’ 2.892 2.04 169 0
 N11  O8’ 2.988 2.16 161 0
Head-to-Tail  N12  O1’ 2.885 2.04 169 3
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Table 4. C-HLO/π hydrogen bonds between the helices observed in the 
structure of peptides, Ac-Gly-Ala-∆Phe-Leu-Xxx--∆Phe-Leu-Xxx--∆Phe-Ala-
Gly-NH2. (Xxx=Val  I, Xxx=Ala II) 
 Peptide I
Donor (D) Acceptor (A) DLA (Å) HLA (Å) D-HLA (°)
CE2_3A  O_1B 3.415 2.64 141
CE2_6A  O_4B 3.384 2.54 151
CE2_9A  O_7B 3.588 2.66 177
CG2_8D  X_3A 3.863 3.05 143
CG2_5D  X_6A 3.868 3.21 128
CA_11B  X_9A 4.102 3.36 135
CG2_8F  X_3C 3.863 3.05 143
CG2_5F  X_6C 3.868 3.21 128
CA_11A  X_9C 4.102 3.36 135
CG2_8B  X_3D 3.863 3.05 143
CG2_5B  X_6D 3.868 3.21 128
CG2_8A  X_3F 3.863 3.05 143
CG2_5A  X_6F 3.868 3.21 128
CA_11D
CA_11E
 X_9F
 X_9G
4.102
4.102
3.36
3.36
135
135
CG2_8D  X_3A 3.863 3.05 143
Peptide II
Donor (D) Acceptor (A) DLA (Å) HLA (Å) D-HLA (°)
CE2_3A  O_4B 3.416 2.71 134
CE2_6A  O_1B 3.508 2.80 134
CB_5F  X_6A 3.589 2.65 168
CD2_7G  X_6A 4.112 3.28 146
CB_5D  X_6B 3.589 2.65 168
CD2_7E  X_6B 4.112 3.28 146
CB_5A  X_6D 3.589 2.65 168
CD2_7A  X_6E 4.112 3.28 146
CB_5C  X_6F 3.589 2.65 168
CD2_7C  X_6G 4.112 3.28 146
X= Centroid of aromatic ∆Phe ring 
A, B, C, D, E, F and G represent chain ID of molecules in crystal packing (Figure 4). 
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Legends to the figures:
Figure 1. Molecular conformation in crystals of. Ac-Gly-Ala-∆Phe-Leu-Val-∆Phe-
Leu-Val-∆Phe-Ala-Gly-NH2.  (a) view perpendicular to the helix axis, (b) view along 
the helix axis, and in crystals of . Ac-Gly-Ala-∆Phe-Leu-Ala-∆Phe-Leu-Ala-∆Phe-
Ala-Gly-NH2. (c) view perpendicular to the helix axis, (d) view along the helix axis. 
(e) and (f) Electron density maps (2Fo-Fc) contoured at 2.0 σ levels for the 
peptides.
Figure 2. Wedge into groove association of interacting helices in the crystal structure 
of Ac-Gly-Ala-∆Phe-Leu-Val-∆Phe-Leu-Val-∆Phe-Ala-Gly-NH2, (a) view for 
antiparallel helices (b) view for parallel helices and in crystals of. Ac-Gly-Ala-∆Phe-
Leu-Ala-∆Phe-Leu-Ala-∆Phe-Ala-Gly-NH2 (c) view for antiparallel helices (d) view 
for parallel helices, Where N- N terminus, C- C terminus. In all the figures, along the 
helix axis, the label corresponds to the terminus closest to the viewer.
Figure 3. Packing of helices in the crystals of Ac-Gly-Ala-∆Phe-Leu-Val-∆Phe-Leu-
Val-∆Phe-Ala-Gly-NH2.  (a) view along the helix axis. (b) view perpendicular to the 
helix axis, and in the crystals of Ac-Gly-Ala-∆Phe-Leu-Ala-∆Phe-Leu-Ala-∆Phe-Ala-
Gly-NH2.  (c) view along the helix (d) view perpendicular to the helix axis. Note that 
in both peptide structures, the central helix is surrounded by six other helices; outer 
helices are either parallel or antiparallel to the central helix. In view (b) and (d) it may 
be seen that the helices are packed in flush with each other. In e) the peptide chains 
are named and the packing of helices in both the peptide crystal structures I and II is 
shown schematically.
Figure 4. a) C-H…O and C-H…π inter helical hydrogen bonds between parallel 
helices in case of Peptide I, b) C-H…O inter helical hydrogen bonds between parallel 
helices in case of Peptide II, (c, d) N-H…O hydrogen bond observed between the 
termini of antiparallel helices in case of Peptide I and II at Leucine-Leucine interface, 
e) Inter helical C-H…π interaction between antiparallel helices at Leucine-Leucine 
interface in case of Peptide I and f) inter helical C-H…π hydrogen bond between 
antiparallel helices at Leucine-Leucine and Alanine-Alanine interfaces in case of 
Peptide II.
Figure 5.   Schematic presentation of the network of weak hydrogen bonds in crystal 
structure of Ac-Gly-Ala-∆Phe-Leu-Val-∆Phe-Leu-Val-∆Phe-Ala-Gly-NH2. (a) the 
network of C-H…π hydrogen bonds.  (b) the network of C-H…O hydrogen bonds, 
and in the crystal structure of Ac-Gly-Ala-∆Phe-Leu-Ala-∆Phe-Leu-Ala-∆Phe-Ala-
Gly-NH2 (c) the network of C-H…π hydrogen bonds, (d) the network of C-H…O 
hydrogen bonds. e) Network of N-H…O hydrogen bond observed in both the peptide 
crystal structures. Arrow points to the acceptor of hydrogen bond and numbers 
represent the number of hydrogen bonds. Note that A represents central helix in both 
the peptides. Helices B and C are parallel to A, whereas D, E, F, G are antiparallel to 
A. The relative orientation of the helices is as depicted in figure 3e.
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FIGURE 1 (a-d)
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FIGURE 1 (e-f)
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FIGURE 2 (a-d)
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FIGURE 3 (a-d)
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FIGURE 3 (e)
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FIGURE 4 (a-f)
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FIGURE 5 
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